Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NP56
UPID:
PDE7B_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NP56; Q5W154
Background:
The cAMP-specific 3',5'-cyclic phosphodiesterase 7B plays a crucial role in hydrolyzing cAMP, a pivotal regulator of numerous vital physiological processes. This enzyme's activity is essential for the modulation of cAMP-mediated neural functions and its metabolism within the brain, highlighting its significance in neural activity regulation.
Therapeutic significance:
Understanding the role of cAMP-specific 3',5'-cyclic phosphodiesterase 7B could open doors to potential therapeutic strategies, especially in neurological disorders where cAMP signaling pathways are implicated.